Table 5.
Haplotypes associated with depression or clinical remission after 8-week antidepressant treatment
| Sample | Gene | Block no. | Haplotypea | Frequency | χ2 | d.f. | P | |
|---|---|---|---|---|---|---|---|---|
| Case | Control | |||||||
| MDD patients and healthy controls | CREB1 | Block 1 | GCACGG | 0.003 | 0.018 | 5.71 | 1 | 0.02 |
| SLC6A3 | Block 1 | CGTGCGGT | 0.089 | 0.134 | 4.83 | 1 | 0.03 | |
| ABCB1 | Block 2 | GCACACACGAGAC | 0.060 | 0.028 | 6.12 | 1 | 0.01 | |
| NTRK2 | Block 1 | GTTAGGGCA | 0.094 | 0.133 | 3.96 | 1 | 0.05 | |
| SLC6A2 | Block 3 | ACCAGA | 0.004 | 0.017 | 3.98 | 1 | 0.05 | |
| Remitter | Non-remitter | |||||||
| MDD patients treated with desipramine or fluoxetine | ABCB1 | Block 1 | ACA | 0.101 | 0.029 | 4.72 | 1 | 0.03 |
| NTRK2 | Block 3 | TCG | 0.839 | 0.717 | 5.63 | 1 | 0.02 | |
| SLC6A4 | Block 1 | TAGC | 0.006 | 0.047 | 5.11 | 1 | 0.02 | |
| Block 1 | TAGA | 0.048 | 0.003 | 4.92 | 1 | 0.03 | ||
| Block 2 | ATTGTAACC | 0.028 | 0.081 | 4.00 | 1 | 0.05 | ||
| MDD patients treated with desipramine | ABCB1 | Block 1 | ACA | 0.132 | 0.018 | 5.31 | 1 | 0.02 |
| NTRK2 | Block 3 | TCG | 0.865 | 0.679 | 6.35 | 1 | 0.01 | |
| Block 3 | CAG | 0.045 | 0.177 | 5.74 | 1 | 0.02 | ||
| SLC6A2 | Block 3 | GCCAGT | 0.134 | 0.012 | 6.79 | 1 | 0.009 | |
| MDD patients treated with fluoxetine | ABCB1 | Block 2 | GCGCACACGAGAC | 0.503 | 0.682 | 4.08 | 1 | 0.04 |
| SLC6A4 | Block 1 | TAGC | 0.000 | 0.085 | 8.37 | 1 | 0.004 | |
Abbreviations: ABCB1, ATP-binding cassette subfamily B member 1; CREB1, cyclic AMP-responsive element binding protein 1; MDD, major depressive disorder; NTRK2, neurotrophic tyrosine kinase type 2 receptor; SNP, single nucleotide polymorphism.
a
Letters with underline indicate the SNPs also showing an association with a nominal P<0.05 in the corresponding SNP-based analysis.